Literature DB >> 9023661

In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii.

L Martinez-Martinez, G Rodriguez, A Pascual, A I Suárez, E J Perea.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9023661     DOI: 10.1093/jac/38.6.1107

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  9 in total

1.  Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.

Authors:  A Bruce Montgomery; Paul R Rhomberg; Tammy Abuan; Kathie-Anne Walters; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

2.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

3.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

Review 4.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

5.  Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

Authors:  M E Falagas; M D Kanellopoulou; D E Karageorgopoulos; G Dimopoulos; P I Rafailidis; N D Skarmoutsou; E A Papafrangas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-23       Impact factor: 3.267

Review 6.  Fosfomycin: Pharmacological, Clinical and Future Perspectives.

Authors:  Anneke Corinne Dijkmans; Natalia Veneranda Ortiz Zacarías; Jacobus Burggraaf; Johan Willem Mouton; Erik Bert Wilms; Cees van Nieuwkoop; Daniel Johannes Touw; Jasper Stevens; Ingrid Maria Catharina Kamerling
Journal:  Antibiotics (Basel)       Date:  2017-10-31

7.  In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae.

Authors:  Wei Yu; Qixia Luo; Qingyi Shi; Chen Huang; Xiao Yu; Tianshui Niu; Kai Zhou; Jiajie Zhang; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2018-04-24       Impact factor: 4.003

8.  Neonatal septicaemia caused by diverse clones of Klebsiella pneumoniae & Escherichia coli harbouring blaCTX-M-15.

Authors:  Subhasree Roy; Rajni Gaind; Harish Chellani; Srujana Mohanty; Saswati Datta; Arun K Singh; Sulagna Basu
Journal:  Indian J Med Res       Date:  2013-04       Impact factor: 2.375

9.  Effect of tetrandrine against Candida albicans biofilms.

Authors:  Lan-Xue Zhao; De-Dong Li; Dan-Dan Hu; Gan-Hai Hu; Lan Yan; Yan Wang; Yuan-Ying Jiang
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.